Objective. Evaluation of the possibility of determining the serum n-terminal pro-brain natriuretic peptide (NT-proBNP) and soluble st2 receptor (sST2) levels for predicting cardiovascular events (CVE) in patients receiving «on-line» hemodiafiltration (HDF).
Material and methods. During the 16 months of the prospective study, 43 patients (60.5% men) receiving «on-line» HDF were followed-up. Two groups of patients were identified depending on the presence/absence of an simultaneous increase in two biomarkers: NT-proBNP≥2093 pg/ml and sST2≥22 ng/ml.
Results. CVE were detected in 11 (25.6%) patients out of 43; CVE were fatal in 4 patients. Repeated CVE during the follow-up period were not identified. Serum NT-proBNP level was 1808 (757–2580) pg/ml, sST2 – 22 ± 5.9 ng/ml. Among patients with a simultaneous increase in two biomarkers (n=12), CVE developed in 6 (50%) patients, and among patients without an increase in NT-proBNP + sST2 (n=31) – in 5 (16.1%). The incidence of CVE was significantly higher in the presence of a simultaneous increase in two biomarkers: NT-proBNP ≥2098 pg/ml and sST2 ≥22 ng/ml (P<0.05). Fatal CVE developed in 3 (25%) patients with an increase in the levels of both biomarkers, which was significantly more frequent than in patients without an increase in NT-proBNP + sST2 (P <0.05).
Conclusion. For predicting CVE in patients receiving «on-line» HDF, it is advisable to use a combination of biomarkers (NT-proBNP + sST2). Patients with serum NT-proBNP ≥2098 pg/ml in combination with sST2 ≥22 ng/ml should be considered to be at high risk for CVE.

Keywords: sST2, programmed hemodialysis, hemodiafiltration, NT-proBNP, cardiovascular diseases, biomarkers